Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perturbing the HIV Reservoir With Immune Stimulation
NCT02707692Completed
- Sponsor
- University of California, San Diego
- Start
- Aug 2016
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Randomised, double-blind trial of Fluarix and 23-valent pneumococcal polysaccharide vaccine in human immunodeficiency virus infection (HIV) (6 arms), sponsored by University of California, San Diego. Primary endpoint: CD4+ T Cell-associated HIV RNA Transcription at Day 30. Started Aug 2016; status: completed.
02
Drugs
Fluarix23-valent pneumococcal polysaccharide vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02707692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707692.